#Aim labs ranks plus#

For some regions, figures were compiled through the publicly available PwC/CB Insights MoneyTree™ Report. Venture capital (VC) funding-Figures for all of 2019 and all of 2020.

#Aim labs ranks plus#

NIH funding-Taken from the publicly available NIH RePORT database, for the current federal fiscal year through March 1, plus all of fiscal year 2020, which ran from October 1, 2019, through September 30, 2020.GEN ranks regions based on five quantifiable criteria: Those highs are reflected in high regional numbers seen in GEN’s annual ranking of the nation’s top 10 biopharma clusters. clusters, 2020 saw record-high amounts of lab space and NIH funding, as well as record-high numbers of jobs and patents. Judging from the numbers reported by the nation’s top U.S. PitchBook and the National Venture Capital Association recorded even more activity in the “biotech and pharma” category of $27.4 billion last year, up from $17.3 billion in 2019. Yet the industry scramble to develop vaccines and drugs against COVID-19 and diagnostics for the virus also propelled the life sciences to record high venture capital of $23.5 billion in 626 deals in eight life sciences categories covered by GEN (biotechnology, disease diagnosis, drug delivery, drug development, drug discovery, drug manufacturing, pharmaceutical distribution and wholesale, and pharmaceuticals/drugs), according to the PwC/CB Insights quarterly MoneyTree™ Report.